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Comparative Risk of Cardiovascular Outcomes Between Topical and
Oral Nonselective NSAIDs in Taiwanese Patients With Rheumatoid
Arthritis
Tzu-Chieh Lin, BPharm, PhD; Daniel H. Solomon, MD, MPH; Sara K. Tedeschi, MD, MPH; Kazuki Yoshida, MD, MPH;
Yea-Huei Kao Yang, BPharm
Background-—Topical NSAIDs have less systemic absorption than oral NSAIDs. We examined the risk of cardiovascular events
associated with nonselective topical NSAIDs versus oral NSAIDs among patients with rheumatoid arthritis in Taiwan.
Methods and Results-—We conducted a retrospective cohort study that included patients with incident rheumatoid arthritis who
were newly starting therapy with nonselective topical NSAIDs or oral NSAIDs. We used the Taiwan National Health Insurance
Research Database (NHIRD). The ﬁrst date patients received either type of NSAID was deﬁned as the index date. NSAID exposures
continued until there was a treatment gap of >30 days. The main outcome was composite cardiovascular events, including
myocardial infarction, unstable angina, heart failure, stroke, or revascularization. Follow-up was censored at treatment
discontinuation, switch or addition of other NSAID category, cardiovascular outcome, death, or the end of the study. Propensity
score weighted Cox regression models were used to compare the risk of cardiovascular events between topical NSAIDs and oral
NSAIDs. There were 10 758 and 78 056 treatment episodes for topical and oral NSAIDs identiﬁed. After weighting by propensity
score, the cohorts were well balanced over all covariates. The crude cardiovascular event rate was 1.87 per 100 person-years for
topical NSAIDs and 2.14 per 100 person-years for oral NSAIDs. Results of propensity score weighted Cox regression found the
topical NSAID group had 36% lower risk for cardiovascular events compared with the oral NSAID group (hazard ratio, 0.64; 95%
conﬁdence interval, 0.43–0.95).
Conclusions-—We found topical NSAID users experienced a reduced risk of cardiovascular events compared with oral NSAID users.
If future studies with a larger sample size and longer follow-up conﬁrm these results, NSAID prescribing might change accordingly.
( J Am Heart Assoc. 2017;6:e006874. DOI: 10.1161/JAHA.117.006874.)
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P atients with rheumatoid arthritis (RA) have had a 1.5- to2.0-fold higher risk for coronary artery disease, myocar-
dial infarction, and stroke than the general population,1,2 and
they commonly receive NSAIDs for symptom relief. In recent
years, studies have found that oral NSAIDs are associated
with increased cardiovascular risks,3–5 leading to special
concerns of NSAID safety in the population with RA. A
recent meta-analysis and an observational study found
similar increased cardiovascular risk across oral nonselective
NSAIDs,6 whereas higher risk was found in selective
cyclooxygenase 2 (COX-2) inhibitors versus oral nonselective
NSAIDs.7 However, nonselective NSAIDs were not associ-
ated with increased cardiovascular mortality in patients with
RA.8
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Topical NSAIDs may provide symptom relief without
associated systemic adverse events because of favorable
pharmacokinetic and pharmacodynamic properties. Topical
NSAIDs reach higher local and lower systemic concentration
in the body than oral NSAIDs. Topical diclofenac has 5- to
17-fold lower systemic exposure than its oral form.9 Local
skin reactions are common adverse events in people taking
topical NSAIDs, but they are generally transient and not
severe. Topical NSAIDs for musculoskeletal symptoms were
at least as efﬁcacious as oral NSAIDs in a recent Cochrane
systematic review.10 The follow-up length in most clinical
trials included in the meta-analysis was <12 weeks,11–13
which was not sufﬁcient to evaluate the long-term safety
signals, either cardiovascular or renal adverse events. Only a
few post hoc analyses compared the cardiovascular risks
between topical and oral NSIAIDs. One found topical
diclofenac had fewer cardiovascular-related adverse events
than the oral form (1.5% versus 3.5%) during 12 weeks of
follow-up.13
In 2015, the US Food and Drug Administration issued a
drug safety communication that strengthened the warning
that nonaspirin NSAIDs can cause heart attacks, heart failure,
or strokes.14 Speciﬁcally, the risk of adverse cardiovascular
events can occur as early as the ﬁrst weeks of using NSAIDs,
and can occur in patients with or without heart disease or risk
factors for heart disease. Therefore, it is crucial to ﬁnd a safer
alternative for oral NSAIDs, especially for patients with RA
who are frequently exposed to and have elevated cardiovas-
cular risks compared with the general population and patients
with osteoarthritis. On the basis of the pharmacokinetic/
pharmacodynamic proﬁle of the topical NSAIDs and results
from a short-term clinical trial,13 we hypothesize that the long-
term cardiovascular risk in topical nonselective NSAID users
may be lower than the risk in oral nonselective NSAID users in
typical practice. In this study, we used the national claims
data from Taiwan to compare the risk of composite cardio-
vascular events between topical and oral nonselective NSAIDs
in patients with RA.
Methods
Data Source
Data sets were obtained from Taiwan’s NHIRD. Taiwan
launched a single-payer NHI program in 1995, and by 2010,
99% of the population was enrolled. The NHIRD contains
demographic data of enrollees, information on healthcare
professionals and medical facilities, and service records and
expenditure claims from inpatient, ambulatory care, and
contracted pharmacies for reimbursement purposes. Large
computerized databases are provided to scientists in Taiwan
for research purposes. Patient identiﬁcations in NHIRD were
double encrypted and deidentiﬁed. This study’s protocol was
reviewed and approved by the Institutional Review Board of
National Cheng Kung University Hospital (Tainan, Taiwan). The
requirement for informed consent from patients is waived for
studies using NHIRD.
Study Design and Population
A retrospective cohort was constructed and included
Taiwanese patients with incident RA (International Classiﬁ-
cation of Diseases, Ninth Revision [ICD-9] code: 714.XX,
excluding 714.3), aged >18 years, who initiated therapy with
a disease-modifying antirheumatic drug (DMARD) between
January 1, 2002 and December 31, 2010. We required these
patients to have at least 2 RA diagnoses, 7 days apart, and
to receive at least 1 DMARD prescription within 365 days
from the ﬁrst RA diagnosis. The positive predictive value of
this algorithm was validated and ranged from 86.2% to
88.9% in the US claims database.15 Furthermore, patients
had to receive any topical or oral nonselective NSAID after
the ﬁrst RA diagnosis. The ﬁrst date patients started topical
or oral nonselective NSAID therapy was deﬁned as the index
date, and the 6-month period before the index date was the
baseline period for covariate assessment. Patients were
excluded if they had any NSAID exposures, cancer, HIV (ICD-
9 code: 042 or V08), psoriatic arthritis (ICD-9 code: 696), or
ankylosing spondylitis (ICD-9 code: 720) claims or were
without complete enrollment information during the baseline
period.
Clinical Perspective
What Is New?
• We found Taiwanese patients with rheumatoid arthritis who
were receiving topical nonselective NSAIDs experienced a
reduced risk of cardiovascular events compared with those
receiving oral nonselective NSAIDs, and the results are
consistent in patients with preexisting cardiovascular
diseases.
What Are the Clinical Implications?
• The US Food and Drug Administration strengthened the
label warnings for the risk of cardiovascular events with all
NSAID use, regardless of the routes of administration and
preexisting cardiovascular diseases.
• Topical NSAIDs may provide symptom relief without asso-
ciated systemic adverse events because of favorable
pharmacokinetic and pharmacodynamic properties, and we
found topical nonselective NSAIDs may be a safer alterna-
tive for relieving muscle-skeletal pain in patients with
cardiovascular diseases.
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Topical or Oral Nonselective NSAID Treatment
Episodes
All topical or oral nonselective NSAID prescription records
were retrieved from inpatient, outpatient, and pharmacy
claims by World Health Organization Anatomical Therapeutic
Chemical (ATC) codes. Patients were classiﬁed into topical
(World Health Organization ATC code: M02AA or D11AX18) or
oral (World Health Organization Anatomical Therapeutic
Chemical (ATC) code: M01A or M01B, excluding M01AH)
nonselective NSAID group based on the NSAID they received
on the index date. We conﬁrmed the persistence in each
treatment episode of either topical or oral nonselective NSAID
by allowing a 30-day grace period and restricted to a
minimum of 15 days of exposure. Patients were eligible to
contribute >1 treatment episode if they were free of any
NSAIDs for at least 180 days from the end of the last episode.
Patients were censored on the last date covered by drugs in
each episode, the date switched to or added on the other
formulations of nonselective NSAIDs (ie, topical or oral), the
date of study outcomes, death, or December 31, 2010.
Outcomes and Covariates
The main study outcome in this study was the composite of
cardiovascular events, including myocardial infarction,
unstable angina, heart failure, stroke (ischemic, hemor-
rhagic, and transient ischemic attack), and revascularization
(coronary artery bypass graft/percutaneous coronary inter-
vention). Each outcome record was retrieved from the
inpatient claims plus corresponding diagnosis (ICD-9) and/
or procedure (Taiwan NHI) codes. We included patient
demographic information (age, sex, and income levels),
comorbid conditions (diabetes mellitus, hypertension, hyper-
lipidemia, myocardial infarction, stroke, angina, upper
gastrointestinal tract disease, Alzheimer dementia, Parkin-
son disease, fractures, osteoporosis, liver disease, chronic
back pain, gout, and falls), and comedications (proton pump
inhibitors, H2-receptor antagonists, antithrombotic therapy,
benzodiazepine, selective serotonin reuptake inhibitor, b
blockers, angiotensin-converting enzyme inhibitor, angioten-
sin receptor blocker, thiazide diuretics, loop diuretics, oral
steroid, and anticonvulsant) that were correlated with
cardiovascular diseases (Table S1 provides a detailed
variable list and codings).7 These variables plus DMARDs
were considered in propensity score (PS) models. We
further categorized DMARD exposures into 7 mutually
exclusive regimens: methotrexate combination, methotrex-
ate-free combination, methotrexate only, hydroxychloroquine
only, sulfasalazine only, other traditional DMARDs, and any
biologic DMARD-containing regimens. Patient demographic
information was determined on the index date, and other
covariates were measured within 6 months before each
treatment episode.
Statistical Analyses
We used the standardized mean difference to test the
differences in baseline covariates between topical and oral
nonselective NSAID treatment episodes. Differences >0.1
standardized mean difference (10%) represent a clinically
signiﬁcant difference. Kaplan-Meier method was used to plot
unadjusted survival curves. To better control confounding and
preserve statistical power, we calculated the stabilized inverse
probability of treatment weights (IPTWs) for each treatment
episode and weighted them in the baseline table and Cox
proportional hazard regression models, using oral nonselec-
tive NSAIDs as the reference. Robust variance estimator was
adopted in the Cox models to ﬁx the potential correlations
within episodes contributed by the same patients. A PS was
calculated for each patient using multivariable logistic
regression model conditioning on all covariates included in
Table S1. A stabilized IPTW was then developed by multiplying
the IPTW in topical and oral nonselective NSAID groups with
marginal prevalence of the treatment actually received.16 The
mean of the stabilized IPTW was checked to examine outliers
and whether the cohort was weighted appropriately.
We conducted sensitivity and subgroup analyses to test
the robustness of our study. First, a 1:7 ratio PS greedy
matching algorithm was applied to examine our results in a
matched cohort.17 Second, although all patients included in
our cohort had ever received any DMARD within the ﬁrst year
of RA diagnosis, some NSAID treatment episodes may start
before DMARD initiation (eg, started on the ﬁrst diagnosis
code) based on our algorithm for identifying RA cases. We
further compared the cardiovascular event risk between
topical and oral nonselective NSAIDs in treatment episodes
started after DMARD initiation. Third, we extended the grace
period for exposures to 60 days. Finally, we examined our
results in serial subgroups deﬁned by age, sex, and cardio-
vascular disease history. All analyses were conducted using
SAS version 9.4.
Results
Baseline Characteristics of Topical and Oral
Nonselective NSAID Treatment Episodes
There were 46 265 patients with incident RA who met our
inclusion criteria, and 46 017 of them (99.5%) received
topical or oral NSAIDs after meeting the RA diagnosis. We
further identiﬁed 10 758 and 78 056 topical and oral NSAID
treatment episodes, respectively, from this cohort (Figure 1).
Restarting treatment was common; on average, there were 2
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episodes per patient during the follow-up. Topical nonselec-
tive NSAID users were older, more frequently had most
comorbid conditions (hypertension, stroke, upper gastroin-
testinal tract disease, fracture, osteoporosis, back pain,
osteoarthritis, and chronic renal disease), and used comed-
ications (proton pump inhibitors, antithrombotic therapy,
benzodiazepines, angiotensin receptor blockers, and anticon-
vulsants) compared with oral nonselective NSAID users. More
single or combination use of methotrexate and biologic
DMARD exposures were observed in topical nonselective
NSAID groups (Table 1 and Table S2). Nevertheless, after
weighting by IPTW, the weighted cohort showed excellent
balance between 2 groups across all covariates (mean of
IPTW, 1.000.17).
Incidence and Risk of Composite Cardiovascular
Events in Topical and Oral Nonselective NSAID
Treatment Episodes
The crude cardiovascular event rates were 1.83 per 100 per-
son-years in the topical nonselective NSAID group and 2.14
per 100 person-years in the oral nonselective NSAID group
(Table 2). The breakdown of numbers of composite cardio-
vascular events was presented in Table S3. The Kaplan-Meier
survival curve demonstrated that the topical nonselective
NSAID group had a trend for higher event-free survival during
the follow-up than the oral nonselective NSAID group (P=0.25
for log-rank test) (Figure 2). Both of the IPTW weighted and
multivariable Cox regression models found topical NSAID
users had signiﬁcantly lower risk of composite cardiovascular
events compared with oral NSAID users: hazard ratio (HR;
IPTW weighted model), 0.64 (95% conﬁdence interval [CI],
0.43–0.95); and HR (multivariable model), 0.54 (95% CI, 0.37–
0.77) (Table 2).
Results of sensitivity analyses are shown in Figure 3. We
ﬁrst matched 6722 and 47 024 topical and oral nonselective
NSAID treatment episodes by PS in a 1:7 ratio and found
consistent results: HR, 0.52 (95% CI, 0.27–0.98). After
excluding episodes started before DMARD initiation, there
were 9366 topical and 61 762 oral nonselective NSAID
treatment episodes identiﬁed for analysis. Similar results
were found in this sensitivity analysis (HR, 0.67; 95% CI, 0.44–
1.02). Consistent direction of HRs was found when we
extended the grace period to 60 days and in subgroup
analyses.
Discussion
Theoretically, topical NSAIDs may have lower systemic
adverse events than oral NSAIDs because of pharmacokinetic
and pharmacodynamic actions. In this retrospective cohort of
Taiwanese patients with incident RA, aged >18 years, we
found the incidence and risk of composite cardiovascular
events were signiﬁcantly lower in topical nonselective NSAID
users than in those receiving oral nonselective NSAIDs in the
primary analysis. The direction of results was consistent
across sensitivity analyses. However, these analyses were not
statistically signiﬁcant because of limited power.
To our knowledge, the current study was the ﬁrst head-to-
head comparison of the cardiovascular outcomes in patients
with RA who were receiving topical or oral nonselective
NSAIDs. There are several preclinical and clinical studies
suggesting that topical NSAIDs have comparable efﬁcacy in
symptom relief in osteoarthritis and inﬂammatory arthri-
tis10,18–20 and fewer gastrointestinal tract and hepatic
adverse effects with their oral forms in patients with
arthritis.10,21 However, these comparisons of safety outcomes
Figure 1. Inclusion ﬂow chart. AS indicates ankylosing
spondylitis; DMARD, disease-modifying antirheumatic drug; PsA,
psoriatic arthritis; and RA, rheumatoid arthritis.
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Table 1. Characteristics of Treatment Episodes in the Original and PS Adjusted Cohorts Using Topical or Oral Nonselective
NSAIDs
Characteristics
Original Cohort IPTW Adjusted
Topical NSAIDs
(N=10 758)
Oral NSAIDs
(N=78 056) SMD*
Topical NSAIDs
(N=10 687)
Oral NSAIDs
(N=78 097) SMD*
Age, mean (SD), y 55.1 (15.4) 51.7 (15.1) 0.22 52.1 (16.0) 52.1 (15.2) 0.00
Female sex, % 82.3 76.0 0.22 77.0 76.8 0.00
Income, % 0.10 0.01
Low 3.4 3.0 3.0 3.0
Middle 36.5 41.3 40.2 40.7
High 60.1 55.7 56.8 56.3
Comorbid conditions, %
Diabetes mellitus 12.4 9.9 0.08 10.5 10.3 0.01
Hypertension 26.5 22.1 0.10 23.1 22.7 0.01
Hyperlipidemia 14.2 11.6 0.08 12.2 11.9 0.01
Myocardial infarction 0.5 0.2 0.03 0.3 0.3 0.00
Stroke 4.6 2.2 0.13 2.6 2.5 0.00
Angina 2.3 1.8 0.04 2.0 1.8 0.01
Upper gastrointestinal
tract disease
18.5 13.3 0.14 14.6 14.0 0.02
Fractures 6.4 3.0 0.16 3.8 3.5 0.02
Osteoporosis 8.5 4.9 0.15 5.6 5.3 0.01
Liver disease 13.9 10.6 0.10 11.2 11.0 0.01
Chronic back pain 36.8 29.6 0.15 31.0 30.5 0.01
Gout 8.3 11.4 0.10 11.1 11.0 0.00
Heart failure 2.4 1.5 0.07 1.7 1.6 0.01
Osteoarthritis 31.1 24.4 0.15 25.2 25.2 0.00
Chronic renal disease 2.6 1.0 0.12 1.3 1.2 0.01
Comedications, %
Proton pump inhibitor 8.1 4.2 0.16 4.9 4.7 0.01
Antithrombotic therapy 8.6 5.5 0.12 6.2 5.9 0.02
b Blockers 17.2 13.6 0.10 14.4 14.1 0.01
ACEI 6.5 5.5 0.03 5.8 5.6 0.01
ARB 12.1 7.9 0.14 9.0 8.5 0.02
Oral steroid 37.9 41.0 0.06 41.0 40.6 0.01
DMARD regimens, %† 0.20 0.01
No use 69.3 65.6 65.7 66.0
Methotrexate
combination
7.1 5.9 6.0 6.0
Other methotrexate-free
combination
3.9 3.6 3.6 3.6
Methotrexate only 1.4 2.3 2.2 2.2
Hydroxychloroquine only 12.5 15.6 15.6 15.3
Sulfasalazine only 3.3 6.0 5.5 5.6
Continued
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between topical and oral NSAIDs were often limited to small
sample size with <12 weeks of follow-up, and there were few
cardiovascular outcome studies for NSAIDs in patients with
RA. In 2011, Roth et al evaluated the safety outcomes in
topical and oral diclofenac users by pooling data from two
12-week, double-blind, randomized controlled trials.13,21,22
There were 927 patients, aged between 40 and 85 years
(n=465 for topical diclofenac, n=462 for oral diclofenac), from
Canada and the United States with osteoarthritis included in
this post hoc analysis. They found the topical diclofenac group
had lower rates for any vascular or cardiac-related adverse
event (1.5% versus 3.5%; P=0.055) and cardiac disorder (0.2%
versus 1.3%, including angina, acute myocardial infarction,
arrhythmia, coronary artery disease, and palpitations) in
comparison to the oral diclofenac group during the 12 weeks
of follow-up.13 Our results extend the ﬁndings of Roth and
Fuller from the previous post hoc analysis13 in a large
Taiwanese RA cohort under real-world practices. Compared
with the post hoc analysis,13 our cohort was slightly younger
and included more cardiovascular diseases (heart failure,
stroke, and revascularization) as study outcomes. Our results
also supported that topical nonselective NSAID users had a
lower cardiovascular event rate (crude rates, 1.8 per
100 person-years for topical nonselective NSAIDs and 2.1
per 100 person-years for oral nonselective NSAIDs), and
there was a 36% lower risk for the composite cardiovascular
events in topical nonselective NSAID users than in oral
nonselective NSAID users (PS adjusted HR, 0.64; 95% CI,
0.43–0.95).
We also found topical nonselective NSAID users may have
a lower risk for cardiovascular events in the subgroup of
patients with preexisting cardiovascular diseases within
6 months before each treatment episode, deﬁned by having
myocardial infarction, stroke, angina, or heart failure. On the
basis of results from a recent meta-analysis,3 the US Food
and Drug Administration strengthened the warning that oral
nonselective NSAIDs were associated with a higher incidence
of excess serious cardiovascular events or death in patients
with preexisting cardiovascular disease, recent MI, and severe
heart failure.14 Consideration of using topical nonselective
NSAIDs in patients with cardiovascular diseases may have 2
advantages. First, one of the known mechanisms for increas-
ing cardiovascular risk among COX-2 inhibitors and oral
nonselective NSAIDs is inhibition of the COX-2 enzyme.23 Use
of topical nonselective NSAIDs in patients with known
cardiovascular diseases may provide beneﬁt from less
systemic inhibition of COX-2 enzyme and thus lower cardio-
vascular risk. This has been evidenced in a recent randomized
crossover pharmacodynamic study; it found that topical
diclofenac only inhibited approximately half of COX-2 as oral
diclofenac did in the systemic form.9 Second, the potential of
drug-drug interaction between aspirin and oral nonselective
Table 1. Continued
Characteristics
Original Cohort IPTW Adjusted
Topical NSAIDs
(N=10 758)
Oral NSAIDs
(N=78 056) SMD*
Topical NSAIDs
(N=10 687)
Oral NSAIDs
(N=78 097) SMD*
Other DMARD
monotherapy
0.7 0.4 0.5 0.5
bDMARD regimens 1.8 0.7 0.8 0.8
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; bDMARD, biologic-containing DMARD; DMARD, disease-modifying antirheumatic drug; IPTW,
inverse probability of treatment weight; PS, propensity score; and SMD, standardized mean difference.
*SMD ≥0.1 represented signiﬁcant differences.
†Although using any DMARDs was one of the inclusion criteria, some patients may start taking NSAIDs before DMARDs or stop DMARDs during the follow-up. Methotrexate combination
indicates biologic-free methotrexate combination regimens; other methotrexate-free combination, biologic- and methotrexate-free combination regimens; and bDMARD regimens, any
monotherapy or combination regimen containing biologics.
Table 2. Incidence and Risk of Composite Cardiovascular Events in Topical and Oral Nonselective NSAID Users
Type of NSAID Use
Follow-Up,
Person-Years
No. of
Events
Crude Incidence
per 100 Person-Years
IPTW Weighted
Cox Model*†
Multivariate
Cox Model*‡
Topical (N=10 758) 1854.6 34 1.83 0.64 (0.43–0.95) 0.54 (0.37–0.77)
Oral (N=78 056) 20 205.3 433 2.14 REF REF
IPTW indicates inverse probability of treatment weight; and REF, reference.
*Data are given as hazard ratio (95% conﬁdence interval).
†IPTW was derived on the basis of the propensity score, which was calculated from the multivariable logistic regression model, conditional on all variables in Table 1.
‡Adjusted for all covariates listed in the Methods.
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NSAIDs might be an issue in patients with known cardiovas-
cular diseases because aspirin is the anchor drug for
secondary prevention of cardiac thrombotic events. In 2016,
Rowcliffe et al found oral diclofenac did inhibit the beneﬁcial
action of aspirin by reversibly binding to the COX-1 enzyme,
resulting in a signiﬁcant reduction in platelet inhibition,
whereas no interaction was observed between topical
diclofenac and aspirin.24 This drug-drug interaction could
contribute to aspirin therapy failure in patients who under-
went secondary prevention for myocardial infarction or
strokes.25 Currently, the topical NSAIDs have the same
warnings and precautions for cardiovascular events with their
oral form in their package insert in the United States.26 Our
ﬁndings suggest a potential beneﬁcial role of topical nonse-
lective NSAIDs in patients with preexisting cardiovascular
diseases, which warrant further conﬁrmation in future larger
studies.
There were several strengths in our study. First, we chose
the population with RA, who commonly use oral or topical
NSAID treatments, providing us a large cohort to examine
the association. Second, we included many potential
confounders from our claims database and used several
explicit pharmacoepidemiological methods, including PS
weighting and matching; distributions of covariates showed
excellent balance across groups after weighting. Several
limitations should be addressed. First, although we adopted
a validated algorithm to identify patients with incident RA by
acquiring all patients who received any DMARD within the
ﬁrst year of diagnosis, patients may start NSAID therapy ﬁrst
before the DMARD initiation in typical clinical practices. We
further examined the study outcomes in treatment episodes
exclusively started after DMARD initiation and found con-
sistent rates (1.90 in topical versus 2.09 in oral NSAIDs/
100 person-years) and HRs. Therefore, the effects of timing
of starting DMARDs seem to be minimal in our study.
Second, the number of composite cardiovascular events
(N=34) was limited in the topical nonselective NSAID groups,
which prohibited us to compare the risk in individual
cardiovascular outcomes. Third, the window for ascertain-
ment of cardiovascular disease history and other comorbidi-
ties in the current study was 6 months. This is a tradeoff to
get an extended baseline period or a larger sample size for
Figure 2. Kaplan-Meier estimates for composite cardiovascular events (P=0.2453 for log-rank test).
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treatment episodes. It is possible that we underestimated
the prevalence of cardiovascular disease history and other
comorbidities, especially MI and stroke, leading to diminish-
ing the effectiveness of propensity scoring to control for
potential confounding. However, the rates observed in our
study were within the range of published Asian RA
literature.27,28 A recently published study also found that
using all available data to capture baseline covariates may
have higher sensitivity, but did not meaningfully change the
overall treatment effect estimates.29 Third, the mean follow-
up duration in the topical nonselective NSAID group was
2 months, reﬂecting the short-term treatment pattern of
topical NSAIDs in the real-life setting. Although we had
longer follow-up and events when we extended the treat-
ment gap to 60 days, the effects attenuated, possibly
because of misclassiﬁcation bias. The exposure scenario
under more extended treatment gaps was usually closer to
the intent-to-treat design, which aims to provide more
conservative results but also may underestimate the treat-
ment adverse effects when patients did not fully adhere to
the regimens.30 Nevertheless, on the basis of the reviews
and latest statement from the US Food and Drug Admin-
istration, the risk of cardiovascular events can occur as early
as the ﬁrst weeks of using an NSAID.14 Our study could
reﬂect the early cardiovascular risk information in patients
newly taking either topical or oral NSAIDs. Fourth, we did
not have information about how patients applied their topical
nonselective NSAIDs to their body in our claims database.
Variations might exist between patients in the amount of
actual doses entering systematic circulation. We also did not
have RA disease activity or inﬂammatory marker (eg,
C-reactive protein or erythrocyte sedimentation rate) infor-
mation in our claims data. It is possible that physicians
prefer oral NSAIDs over topical NSAIDs if patients have
higher disease activity or polyarticular ﬂares. We, therefore,
established a DMARD regimen variable, which included 7
classes of regimens and included previous diagnoses of
osteoarthritis and low back pain as surrogates for RA
disease activity in the PS adjustment. In addition, the
DMARD regimens noted in Table 1 are similar in distribution
across the oral and topical NSAID regimens. We also did not
have smoking information in our claims database. However,
our cohort was predominantly Taiwanese women (80%),
and it was reported that the smoking prevalence was only
4% to 5% during the study period in the governmental
survey.31 Furthermore, the results were consistent in female
and male subgroups. Finally, our study focused on patients
with RA, and results might not be generalized to other
populations, such as patients with osteoarthritis.
In conclusion, our hypothesis-driven study found topical
nonselective NSAIDs were associated with a lower risk for
composite cardiovascular events compared with oral nonse-
lective NSAIDs in Taiwanese patients with RA. Currently, the
US Food and Drug Administration strengthened the label
warnings for the risk of cardiovascular events with all NSAID
use, regardless of the routes of administration and preexisting
cardiovascular diseases.14 Together with the results from a
previous pharmacodynamic study,9,24 our results suggested
that topical nonselective NSAIDs may be a safer alternative
for relieving muscle-skeletal pain in patients with cardiovas-
cular diseases, including those receiving aspirin concurrently.
Future trials or observational studies with more events and
Figure 3. Results of sensitivity analyses. Hazard ratios (HRs) were generated from inverse probability of treatment weight weighted Cox
models. No cardiovascular disease (CVD) history: no myocardial infarction, stroke, angina, or heart failure during the baseline period. Episodes
started after disease-modifying antirheumatic drugs (DMARDs): excluding NSAID episodes that started before DMARD initiation. CI indicates
conﬁdence interval.
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longer-term follow-up will help us understand more about the
risk difference between topical and oral NSAIDs in individual
cardiovascular outcomes. Results in patients with osteoarthri-
tis and head-to-head comparisons of different formulations
within topical NSAIDs (eg, gel, ointment, and patch) are also
needed.
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SUPPLEMENTAL MATERIAL 
 
Table S1. Operational definitions1 
Covariates ICD 9 ATC codes 
Age   
Sex   
Income   
Comorbid conditions   
  Diabetes 250.xx  
  Hypertension 401.xx,402.xx,416.0X  
  Hyperlipidemia 272.xx C10AA, C10AB, C10AD 
  Myocardial infarction 410.xx , 412.xx  
  Stroke 430, 431,432, 433.X1, 434.x1, 435.x, 
436, 437.1x, 437.9x 
 
  Heart failure 428.XX  
  Angina 413.xx  
  CABG/PCI NHI codes  
  Upper gastrointestinal disease 531.xx, 532.xx, 533.xx, and 534.xx  
  Alzheimer dementia 290.xx, 294.xx, 330.xx, 331.xx  
 
N06DA 
  Parkinson 332.xx, 333.0x N04BA, N04BD 
  Fractures 733.1x, 800.xx-829.xx  
  Osteoporosis 733.xx  
 
M05BA, H05BA, H05AA02, 
G03XC01 
  Liver disease 570.xx, 571.xx, 573.xx, 070.xx, 303.xx, 
V11.3, 291.xx, 571.0x, 
571.1x, 571.2x, 571.3x, 357.5x, 535.3x, 
425.5x, 265.2x, E860.0x 
 
  Chronic back pain 720.xx, 721.xx, 722.xx, 723.xx, 724.xx  
  Gout 274.xx  M04AA01 or M04AA51 
Co-medications   
Proton pump inhibitors  A02BC 
H2-receptor antagonists  A02BA 
Antithrombotic therapy  B01AC04, B01AB05, 
B01AB08, B01AB06, 
B01AB10, B01AC07, 
B01AC05, B01AC23, 
B01AA03 (consider include 
B01AB as a whole) 
Benzodiazepine  N03AE, N05BA, N05CD, 
N05CF 
SSRI  N06AB 
Beta blockers  C07AA, C07AB 
ACEI  C09A, C09B 
ARB  C09C, C09D 
Thiazide diuretics  C03A 
Loop diuretics  C03CA 
Oral steroid  H02A,H02B 
Anticonvulsant  N03A 
DMARDs  L01BA01,L04AX03, 
A07EC0, P01BA02, 
L04AA13, L04AX01, 
L04AD01, L04AB01, 
L04AB04 
 
Table S2. Characteristics of treatment episodes in the original and IPTW weighted cohorts 
using topical or oral non-selective NSAIDs (full-list) 
            Original cohort Study cohort 
 Topical 
(N=10,758) 
Oral 
(N=78,056) 
SMD* Topical 
(N=10,687) 
Oral 
(N=78,097) 
SMD* 
Mean age (SD) 55.1 (15.4) 51.7 (15.1) 0.22 52.1 (16.0) 52.1 (15.2) 0.00 
Female,% 82.3 76.0 0.22 77.0 76.8 0.00 
Income,%   0.10   0.01 
  Low 3.4 3.0  3.0 3.0  
  Middle 36.5 41.3  40.2 40.7  
  High 60.1 55.7  56.8 56.3  
Comorbid 
conditions,% 
      
  Diabetes 12.4 9.9 0.08 10.5 10.3 0.01 
  Hypertension 26.5 22.1 0.10 23.1 22.7 0.01 
Hyperlipidemia 14.2 11.6 0.08 12.2 11.9 0.01 
Myocardial   
infarction 
0.5 0.2 0.03 0.3 0.3 0.00 
  Stroke 4.6 2.2 0.13 2.6 2.5 0.00 
  Angina 2.3 1.8 0.04 2.0 1.8 0.01 
  Upper 
gastrointestinal 
disease 
18.5 13.3 0.14 14.6 14.0 0.02 
  Alzheimer 
dementia 
1.7 0.8 0.08 1.0 0.9 0.01 
  Parkinson 1.1 0.5 0.06 0.6 0.6 0.00 
  Fractures 6.4 3.0 0.16 3.8 3.5 0.02 
  Osteoporosis 8.5 4.9 0.15 5.6 5.3 0.01 
  Liver disease 13.9 10.6 0.10 11.2 11.0 0.01 
  Chronic back 
pain 
36.8 29.6 0.15 31.0 30.5 0.01 
  Gout 8.3 11.4 0.10 11.1 11.0 0.00 
  Heart failure 2.4 1.5 0.07 1.7 1.6 0.01 
  Chronic lung 
disease 
10.5 8.4 0.07 9.2 8.7 0.02 
  Peripheral 
vascular disease 
1.8 1.4 0.03 1.5 1.4 0.01 
  Osteoarthritis 31.1 24.4 0.15 25.2 25.2 0.00 
  Cancer 2.4 1.3 0.08 1.5 1.4 0.01 
  Chronic renal 
disease 
2.6 1.0 0.12 1.3 1.2 0.01 
 
  
Table S2. Characteristics of treatment episodes in the original and IPTW weighted cohorts 
using topical or oral non-selective NSAIDs (Continued) 
           Original cohort Study cohort 
 Topical 
(N=10,758) 
Oral 
(N=78,056) 
SMD* Topical 
(N=10,687) 
Oral 
(N=78,097) 
SMD* 
Co-medications       
  Proton pump inhibitor 8.1 4.2 0.16 4.9 4.7 0.01 
  H2-receptor blocker 20.8 21.4 0.01 21.6 21.4 0.01 
  Antithrombotic 
therapy 
8.6 5.5 0.12 6.2 5.9 0.02 
  Benzodiazepine 40.7 34.0 0.14 35.4 34.8 0.01 
  SSRI 3.5 2.5 0.06 2.7 2.6 0.01 
  Beta blockers 17.2 13.6 0.10 14.4 14.1 0.01 
  ACEI 6.5 5.5 0.03 5.8 5.6 0.01 
  ARB 12.1 7.9 0.14 9.0 8.5 0.02 
  Thiazide diuretics 3.7 3.2 0.03 3.5 3.3 0.01 
  Loop diuretics 8.0 5.7 0.09 6.2 6.0 0.01 
  Oral steroid 37.9 41.0 0.06 41.0 40.6 0.01 
  Anticonvulsant 9.2 6.0 0.12 6.6 6.4 0.01 
DMARDs 
Regimens† 
  0.20   0.01 
  No use 69.3 65.6  65.7 66.0  
  Methotrexate 
combination 
7.1 5.9  6.0 6.0  
Other methotrexate-
free combination 
3.9 3.6  3.6 3.6  
  Methotrexate only 1.4 2.3  2.2 2.2  
Hydroxychloroquine 
only 
12.5 15.6  15.6 15.3  
  Sulfasalazine only 3.3 6.0  5.5 5.6  
Other DMARD 
monotherapy 
0.7 0.4  0.5 0.5  
  bDMARD regimens 1.8 0.7  0.8 0.8  
*SMD: standardized mean difference, SMD≥0.1 represented significant differences.  
†Although using any DMARDs was one of inclusion criteria, some patients may start NSAIDs before 
DMARDs or stop DMARDs during the follow-up. Methotrexate combination: biologics-free 
methotrexate combination regimens; other methotrexate-free combination: biologics and methotrexate 
free combination regimens; bDMARD regimens: any mono or combination regimen containing 
biologics. 
‡Abbreviations: SSRI, selective serotonin reuptake inhibitor; ACEI, angiotensin converting enzyme 
inhibitor; ARB: angiotensin receptor blocker. 
 
 
 
Table S3. The breakdown of composite outcomes and death events. 
N (%) Topical NSAID Oral NSAID 
Composite (primary) outcome 34 (100) 433 (100) 
  MI 3 (8.8) 47 (10.9) 
  Angina 5 (14.7) 48 (11.1) 
  Heart failure 13 (38.2) 141 (32.6) 
  Stroke 12 (35.3) 180 (41.6) 
   Revascularization* 3 (8.8) 57 (13.2) 
Death (N) 7 102 
Composite outcome + Death (N) 41 535 
*The numbers do not add up as some people had multiple events.  For example, among revascularization 
cases, 2 (of 3) in topical and 40 (of 57) in oral NSAIDs group cases received MI diagnosis and 
revascularization procedure at the same admission. 
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